Kao Q1
This article was originally published in The Rose Sheet
Executive Summary
Consumer product sales in North America and Europe grew 6% to $233.4 mil. (¥1=$.009) largely on sales of John Frieda Brilliant Brunette launch, Japanese firm states in first quarter (ended June 30) sales and earnings release July 22. Brilliant Brunette launched in January (1"The Rose Sheet" Jan. 5, 2004, p. 4). Worldwide consumer products sales were up 6% to $1.5 bil. Excluding negative currency translation due to depreciation of the yen, consumer sales would have been up 7.2%, firm notes. Net sales advanced 6.5% to $2.06 bil., while net income increased 12.6% to $155 mil. Kao recently announced the appointment of Motoki Ozaki to post of president and CEO, replacing former head Takuya Goto...
You may also be interested in...
John Frieda Targets Brilliant Brunettes With New Hair Care Range
John Frieda is supporting the debut of its Brilliant Brunette hair care collection with print and television ads breaking this spring, the Kao division said
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.